Global /France /Healthcare /Drug Manufacturers - General /ALTAO

Aton

ALTAO

• EPA: ALTAO • Delayed

0.0136EUR -34%

0.0158 USD

As of 5 June 2026, Aton has a market cap of $19.79M USD, ranking #37180 globally and #440 in France. It ranks #3331 in the Healthcare sector, and #1110 in the Drug Manufacturers - General industry.

Global Rank

37180

Country Rank

440

Sector Rank

3331

Industry Rank

1110

Key Stats

Market Cap

$19.79MUSD

17.06M EUR

Enterprise Value

$24.99MUSD

21.51M EUR

Revenue (TTM)

$761.93KUSD

656.93K EUR

EBITDA (TTM)

-$1.02MUSD

-875.57K EUR

Net Income (TTM)

-$134.17KUSD

-115.68K EUR

EBITDA Margin

-133%

Profit Margin

-18%

PS Ratio

26.0

PB Ratio

21.4

Company Profile

Country (HQ)

France

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Ayikoele Atayi open_in_new

Employees

Founded

1998

Website

aton-group.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-34%	243%	232%	232%	171%	186%	110%	-68%	-92%

News

Markets

Exchange	Ticker	Price	Quotes
Euronext Paris (EPA) MIC: XPAR PRIMARY	ALTAO ISIN: FR0004153930 Shares Out.: Shares Outstanding: 1.008B¹ Shares Float: 572.956M² TV: TradingView: EURONEXT: ALTAO SA: Stock Analysis: EPA: ALTAO YF: Yahoo Finance: ALTAO.PA GF: Google Finance: EPA: ALTAO BA: Barron's: ALTAO MS: Morningstar: XPAR: ALTAO	0.0136 EUR	TV: TradingView: EURONEXT: ALTAO SA: Stock Analysis: EPA: ALTAO YF: Yahoo Finance: ALTAO.PA GF: Google Finance: EPA: ALTAO BA: Barron's: ALTAO MS: Morningstar: XPAR: ALTAO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Aton

Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquartered in Strasbourg, France.

Similar Companies

Industry: Drug Manufacturers - General (France)

Name	Market Cap (USD) diff.	PE	Country
Sanofi EPA: SAN	$110.49B 95.26B EUR 558K%	19.9	France
Ipsen S.A. EPA: IPN	$15.75B 13.58B EUR 80K%	31.1	France
Nanobiotix S.A. EPA: NANO	$1.59B 1.37B EUR 8K%	-	France
DBV Technologies S.A. EPA: DBV	$1.24B 1.07B EUR 6K%	-	France
Vetoquinol S.A. EPA: VETO	$1.1B 949.55M EUR 5K%	16.6	France
MedinCell S.A. EPA: MEDCL	$951.96M 820.77M EUR 5K%	-	France

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 4M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 3M%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 2M%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 2M%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 1M%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 1M%	20.5	Switzerland

chevron_leftBack